Dirk Thye - 23 Jan 2026 Form 4 Insider Report for Quince Therapeutics, Inc. (QNCX)

Role
CEO and CMO, Director
Signature
/s/ Brendan Hannah as attorney-in-fact for Dirk Thye
Issuer symbol
QNCX
Transactions as of
23 Jan 2026
Net transactions value
$0
Form type
4
Filing time
23 Jan 2026, 20:25:04 UTC
Previous filing
12 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Thye Dirk CEO and CMO, Director C/O QUINCE THERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO /s/ Brendan Hannah as attorney-in-fact for Dirk Thye 23 Jan 2026 0001638945

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction QNCX Employee Stock Option (Right to Buy) Award $0 +1,000,000 $0.000000 1,000,000 23 Jan 2026 Common Shares 1,000,000 $3.08 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting with 1/48th vesting on the date of grant and the remaining options vesting on the 1st day of each subsequent month, such that the total number of shares shall be fully vested on December 1, 2029.